<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396238</url>
  </required_header>
  <id_info>
    <org_study_id>STAR Trial</org_study_id>
    <nct_id>NCT02396238</nct_id>
  </id_info>
  <brief_title>Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)</brief_title>
  <acronym>STAR</acronym>
  <official_title>Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of the Celution
      Device in the processing of an autologous graft consisting of adipose derived regenerative
      cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The STAR Trial is a prospective, randomized, multi-center device trial intended to assess
      safety and efficacy of subcutaneous administration of Celution processed ADRCs into fingers
      of patients with hand dysfunction due to scleroderma.

      Following informed consent and screening evaluations, eligible subjects will undergo
      pre-operative testing. Subjects will then undergo fat harvest through small volume
      liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to
      isolate and concentrate ADRCs for immediate subcutaneous administration under local
      anesthesia. Subjects will be randomly assigned to receive ADRCs (40 million cells) or a
      visually-matched placebo in a 1:1 ratio. All subjects will receive subcutaneous
      administration of test substance (ADRC or placebo) into all fingers of both hands. Following
      completion of all 48 week visits and database lock, placebo treated subjects will be offered
      treatment with their ADRCs cells should they continue to qualify according to the
      inclusion/exclusion criteria and should they wish to be treated with ADRCs and agree to the
      fat harvest procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cochin score</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cochin score</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Raynaud's Condition Score</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cochin Score</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Raynaud's Condition Score</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physician and Patient Global Assessment</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hand Mobility in Scleroderma (HAMIS)</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Digital ulcer count</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rodnan Score</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Grip strength and pinch strength</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Finger circumference (with hand volume)</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>1st corner distance and sum of 2nd, 3rd and 4th corner distances</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The EuroQOL five dimensions questionnaire (EQ-5D)</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events, Serious Adverse Events</measure>
    <time_frame>up to 48 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Scleroderma</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Raynaud Phenomena</condition>
  <condition>Raynaud's Disease</condition>
  <arm_group>
    <arm_group_label>Adipose Derived Regenerative Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celution Device</intervention_name>
    <description>ADRCs prepared using the investigational Celution Device</description>
    <arm_group_label>Adipose Derived Regenerative Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Males or females ≥ 18 and ≤ 70 years of age

          2. Diagnosis of diffuse cutaneous scleroderma (duration &gt; 5 years) or limited cutaneous
             scleroderma.

          3. Cochin score ≥ 20 units

          4. Ability to safely undergo liposuction

          5. Symptoms consistent with Raynaud's Phemomena

          6. Compliant with standard preventative recommendations

        Key Exclusion Criteria:

          1. Body Mass Index &lt; 18 kg/m2

          2. Active infection in any finger during screening period or infection in any finger
             requiring antibiotics in the 30 days prior to the Screening Visit

          3. Active infection at the potential site(s) of fat harvest during the screening period

          4. Contractures of any finger or ulceration at point of injection precluding completion
             of injection procedure

          5. Amputation of any finger proximal to the proximal interphalangeal joint or any
             amputation in more than one finger

          6. Diagnosis of Rheumatoid Arthritis

          7. Inflammatory arthritis of the hand, including significant osteoarthritis, that is not
             due to scleroderma or significant acute inflammation in the hand that is due to
             scleroderma, as per the investigator's clinical judgment

          8. Oral cyclophosphamide exceeding 2 mg/kg/day, any intravenous cyclophosphamide,
             methotrexate exceeding 25 mg/week, mycophenolate mofetil exceeding 3 gm/day,
             hydoxychloroquine exceeding 7 mg/kg/day or azathioprine exceeding 300 mg/day or any
             other immunosuppressive medication in the 90 days prior to the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Kesten, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytori Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Rheumatology, PLLC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

